PCSK9 and familial hyperaldosteronism: Along with a previous study (Sarkar et al., 2020), we have now characterized a total of six LDL-binding–defective PCSK9 mutations (S465L, R469W, R496W, N513D, F515L, and G516V) identified in FH patients and localized to the CM1 region of the CHR domain.